Volume Spike Investor

Boston Scientific (NYSE: BSX) shares are up 7% in strong premarket trading after the company and The University of Rochester Medical Center announced that the landmark MADIT-CRT trial has met its primary endpoint.

The preliminary results showed the cardiac resynchronization therapy defibrillators with a significant 29% reduction in death or heart failure interventions when compared to traditional implantable cardioverter defibrillators.

The news also could affect other implantable device manufacturers such as Medtronic Inc. (NYSE: MDT) and St. Jude Medical Inc. (NYSE: STJ). The favorable trial of Boston Scientific may help the beaten down device market garner some investment attention. — Mike Tarsala